Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Part B IV Iron Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 5895-D

    Medicare Part B Step Therapy Intravenous Iron

    Customize your policy alerts

    Sign up for zing_health Policy 5895-D alerts

    Get alerted when Policy 5895-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of preferred and non-preferred intravenous iron products under Medicare Part B for Zing Health members. Non-preferred products require prior authorization and are covered when specified clinical exception or prior-use criteria are met.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Intravenous Iron
    Policy CodePolicy 5895-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse a preferred intravenous iron product first; request prior authorization and document a qualifying exception for a non-preferred product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Preferred intravenous iron products
    3Non-preferred intravenous iron products
    365 daysPrior-treatment lookback
    Medicare Part BBenefit designation

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Non-preferred product coverage criteria

    A non-preferred product is covered when any one of the following criteria groups is met, provided the requested indication is FDA-approved for any preferred product.

    Qualifying exception

    • Prior use pathway: The member has received treatment with the requested non-preferred product within the past 365 days.within the past 365 days
    • Feraheme exception

      • Feraheme-specific criteria

        • The member has a diagnosis of iron deficiency anemia with intolerance or unsatisfactory response to oral iron and has had documented inadequate response or intolerable adverse event with Infed.
        • The member has a diagnosis of hemodialysis-dependent chronic kidney disease, is receiving supplemental epoetin therapy, and has had a documented inadequate response or intolerable adverse event with both Ferrlecit and sodium ferric gluconate.
        • The member has a diagnosis of chronic kidney disease and has had a documented inadequate response or intolerable adverse event with Venofer.
    • Injectafer exception

      • Injectafer-specific criteria

        • The member has a diagnosis of iron deficiency anemia with intolerance or unsatisfactory response to oral iron and has had documented inadequate response or intolerable adverse event with Infed.
        • The member has a diagnosis of non-hemodialysis-dependent chronic kidney disease and has had a documented inadequate response or intolerable adverse event with Venofer.
        • The member has a diagnosis of iron deficiency with heart failure categorized as New York Heart Association class II/III.NYHA class II/III
    • Monoferric exception

      • Monoferric-specific criteria

        • The member has a diagnosis of iron deficiency anemia with intolerance or unsatisfactory response to oral iron and has had documented inadequate response or intolerable adverse event with Infed.
        • The member has a diagnosis of non-hemodialysis-dependent chronic kidney disease and has had a documented inadequate response or intolerable adverse event with Venofer.

    Requests for a non-preferred intravenous iron product are within the scope of this program only when the requested indication is FDA-approved for at least one preferred product. Requests for a non-preferred product for an indication that is not FDA-approved for any preferred product are outside the scope of this step therapy program.

    Product-Specific Initial Therapy Criteria

    Feraheme exception

    Feraheme is covered as a non-preferred product when at least one of the following criteria is met.

    Feraheme exception criteria

    • The member has a diagnosis of iron deficiency anemia with intolerance or unsatisfactory response to oral iron and has had documented inadequate response or intolerable adverse event with Infed.
    • The member has a diagnosis of hemodialysis-dependent chronic kidney disease, is receiving supplemental epoetin therapy, and has had a documented inadequate response or intolerable adverse event with both Ferrlecit and sodium ferric gluconate.
    • The member has a diagnosis of chronic kidney disease and has had a documented inadequate response or intolerable adverse event with Venofer.

    Injectafer exception

    Injectafer is covered as a non-preferred product when at least one of the following criteria is met.

    Injectafer exception criteria

    • The member has a diagnosis of iron deficiency anemia with intolerance or unsatisfactory response to oral iron and has had documented inadequate response or intolerable adverse event with Infed.
    • The member has a diagnosis of non-hemodialysis-dependent chronic kidney disease and has had a documented inadequate response or intolerable adverse event with Venofer.
    • The member has a diagnosis of iron deficiency with heart failure categorized as New York Heart Association class II/III.NYHA class II/III

    Monoferric exception

    Monoferric is covered as a non-preferred product when at least one of the following criteria is met.

    Monoferric exception criteria

    • The member has a diagnosis of iron deficiency anemia with intolerance or unsatisfactory response to oral iron and has had documented inadequate response or intolerable adverse event with Infed.
    • The member has a diagnosis of non-hemodialysis-dependent chronic kidney disease and has had a documented inadequate response or intolerable adverse event with Venofer.

    Preferred and Non-Preferred Products

    ProductCoverage designation
    Ferrlecit (sodium ferric gluconate complex)Preferred product — designated for first-line use
    Infed (iron dextran)Preferred product — designated for first-line use
    Sodium ferric gluconatePreferred product — designated for first-line use
    Venofer (iron sucrose)Preferred product — designated for first-line use
    ProductCoverage designation
    Feraheme (ferumoxytol)Non-preferred product — prior authorization and an approved exception required
    Injectafer (ferric carboxymaltose)Non-preferred product — prior authorization and an approved exception required
    Monoferric (ferric derisomaltose)Non-preferred product — prior authorization and an approved exception required

    Authorization and Documentation Requirements

    Prior Authorization

    Exception Review Required for Non-Preferred Products

    Non-preferred intravenous iron products require prior authorization and clinical exception review. Coverage is considered when clinical circumstances exclude use of a preferred product or when qualifying prior treatment supports an exception.

    • This program applies to members who are new to treatment with a non-preferred product for the first time.
    Prior Authorization

    Preferred Products May Still Require Review

    Formulary or preferred status does not guarantee coverage without review. Preferred intravenous iron products may still require clinical prior authorization.

    • Clinical review may be required even when the requested product is preferred or formulary.
    Step Therapy

    Preferred Product First

    Use a preferred intravenous iron product before requesting a non-preferred product, unless the member meets a qualifying clinical exception.

    • Preferred products: Ferrlecit, Infed, sodium ferric gluconate, and Venofer.
    • Non-preferred products: Feraheme, Injectafer, and Monoferric.
    • The program applies when treatment is requested for an indication that is FDA-approved for any preferred product.
    Prior Authorization

    Concurrent Utilization Management Review

    Each referral is reviewed under all utilization management programs implemented for the client. A referral may therefore be subject to concurrent UM requirements in addition to this intravenous iron step-therapy review.

    Documentation Required

    Clinical Exception Documentation

    Submit complete clinical exception documentation with the request. The documentation must establish the member’s diagnosis, the requested product, relevant prior treatment, and the response or intolerance supporting the exception.

    • Identify the applicable diagnosis and requested non-preferred product.
    • Document prior treatment with the relevant preferred product or requested product.
    • Describe the inadequate response or intolerable adverse event, when applicable.
    • For product-specific exceptions, include the required clinical details, such as oral iron intolerance or unsatisfactory response, dialysis status, epoetin use, chronic kidney disease status, or heart failure NYHA class II/III.
    Documentation Required

    Prior Treatment Evidence

    Document qualifying prior treatment evidence. An exception may be supported when the member received the requested non-preferred product within the past 365 days or when the required prior product produced an inadequate response or intolerable adverse event.

    • Record the product, treatment history, and applicable dates for use within the 365-day lookback period.
    • For Feraheme, Injectafer, or Monoferric exceptions, document the required inadequate response or intolerance to the specified prior product or products.
    Denial Risk

    No Approved Exception

    A non-preferred product may be denied when the request does not meet an applicable FDA-approved indication exception or lacks documentation supporting a qualifying exception.

    • The program applies to requests for indications that are FDA-approved for a preferred product.
    • Requests for Feraheme, Injectafer, or Monoferric must satisfy the applicable product-specific exception criteria.
    Denial Risk

    Step Therapy Not Satisfied

    Initial treatment with a non-preferred product is at risk for denial when the member has not used the requested product within the past 365 days and does not meet another qualifying exception criterion.

    • Do not bypass preferred-product step therapy without documented prior use or a qualifying clinical exception.
    • For Feraheme, Injectafer, and Monoferric, document the diagnosis and required inadequate response or intolerance criteria when relying on a product-specific exception.
    Prior Authorization

    Clinical Prior Authorization Still Required

    Preferred or formulary status does not eliminate clinical prior authorization. Submit the required clinical information when requesting any intravenous iron product subject to review.

    • Clinical prior authorization may still apply to Ferrlecit, Infed, sodium ferric gluconate, or Venofer.

    Key Terms

    Preferred product
    DefinitionIntravenous iron products designated by the plan for first-line use under this program.
    Non-preferred product
    DefinitionAn intravenous iron product subject to step therapy and prior authorization for coverage unless the member meets a qualifying exception.
    Clinical exception
    DefinitionA determination that clinical circumstances exclude use of the preferred product or that qualifying prior use of a product supports coverage of the requested non-preferred product.

    Policy Background

    This policy manages Medicare Part B intravenous iron therapy through preferred and non-preferred product designations. Preferred products are used first under the program, while non-preferred products require prior authorization and an approved clinical exception or qualifying prior use for coverage.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Intravenous Iron
    Policy CodePolicy 5895-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse a preferred intravenous iron product first; request prior authorization and document a qualifying exception for a non-preferred product.
    SourceLink
    On This Page
    Coverage CriteriaProduct-Specific Initial Therapy CriteriaPreferred and Non-Preferred ProductsAuthorization and Documentation RequirementsKey TermsPolicy Background